BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Eluri S, Selitsky SR, Perjar I, Hollyfield J, Betancourt R, Randall C, Rusin S, Woosley JT, Shaheen NJ, Dellon ES. Clinical and Molecular Factors Associated With Histologic Response to Topical Steroid Treatment in Patients With Eosinophilic Esophagitis. Clin Gastroenterol Hepatol 2019;17:1081-1088.e2. [PMID: 30213583 DOI: 10.1016/j.cgh.2018.09.005] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Alexander R, Alexander JA, Akambase J, Harmsen WS, Geno D, Tholen C, Katzka DA, Ravi K. Proton Pump Inhibitor Therapy in Eosinophilic Esophagitis: Predictors of Nonresponse. Dig Dis Sci 2021;66:3096-104. [DOI: 10.1007/s10620-020-06633-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
2 Dellon ES, Collins MH, Katzka DA, Mukkada VA, Falk GW, Morey R, Goodwin B, Eisner JD, Lan L, Desai NK, Williams J, Hirano I; ORBIT2/SHP621-302 Investigators. Long-Term Treatment of Eosinophilic Esophagitis With Budesonide Oral Suspension. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00684-4. [PMID: 34182150 DOI: 10.1016/j.cgh.2021.06.020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
3 Hirano I, Furuta GT. Approaches and Challenges to Management of Pediatric and Adult Patients With Eosinophilic Esophagitis. Gastroenterology 2020;158:840-51. [PMID: 31836530 DOI: 10.1053/j.gastro.2019.09.052] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
4 Nhu QM, Aceves SS. Unanswered questions in eosinophilic esophagitis. Ann Allergy Asthma Immunol 2020;124:227-8. [PMID: 31821874 DOI: 10.1016/j.anai.2019.12.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
5 Hirano I, Collins MH, Katzka DA, Mukkada VA, Falk GW, Morey R, Desai NK, Lan L, Williams J, Dellon ES; ORBIT1/SHP621-301 Investigators. Budesonide Oral Suspension Improves Outcomes in Patients With Eosinophilic Esophagitis: Results from a Phase 3 Trial. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00456-0. [PMID: 33887475 DOI: 10.1016/j.cgh.2021.04.022] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 14.0] [Reference Citation Analysis]
6 Nagahara A, Shiotani A, Iijima K, Kamada T, Fujiwara Y, Kasugai K, Kato M, Higuchi K. The role of advanced endoscopy in the management of inflammatory digestive diseases (upper gastrointestinal tract). Dig Endosc 2021. [PMID: 33772880 DOI: 10.1111/den.13982] [Reference Citation Analysis]
7 Kim SJ, Park MI, Kim GH, Lee MW, Jung K, Lee J, Seol SY, Jee SR, Lee HS, Jang JS, Cha JH; Gyeongnam Society of Neurogastroenterology and Motility. Practice Patterns for Eosinophilic Esophagitis Patients in Busan and Gyeongnam: A Korean Multicenter Database Study. J Neurogastroenterol Motil 2021;27:71-7. [PMID: 32699187 DOI: 10.5056/jnm20069] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Dellon ES, Woosley JT, McGee SJ, Moist SE, Shaheen NJ. Utility of major basic protein, eotaxin-3, and mast cell tryptase staining for prediction of response to topical steroid treatment in eosinophilic esophagitis: analysis of a randomized, double-blind, double dummy clinical trial. Dis Esophagus 2020;33:doaa003. [PMID: 32193541 DOI: 10.1093/dote/doaa003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Ananthakrishnan AN. Issue Highlights. Clinical Gastroenterology and Hepatology 2019;17:1011-4. [DOI: 10.1016/j.cgh.2019.03.002] [Reference Citation Analysis]
10 Dellon ES, Gupta SK. A Conceptual Approach to Understanding Treatment Response in Eosinophilic Esophagitis. Clin Gastroenterol Hepatol. 2019;17:2149-2160. [PMID: 30710696 DOI: 10.1016/j.cgh.2019.01.030] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 11.7] [Reference Citation Analysis]
11 Jensen ET, Langefeld CD, Zimmerman KD, Howard TD, Dellon ES. Epigenetic methylation in Eosinophilic Esophagitis: Molecular ageing and novel biomarkers for treatment response. Clin Exp Allergy 2020;50:1372-80. [PMID: 32986922 DOI: 10.1111/cea.13748] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
12 Eluri S, Perjar I, Betancourt R, Randall C, Raja S, Woosley JT, Shaheen NJ, Dellon ES. Heartburn and dyspepsia symptom severity improves after treatment and correlates with histology in adults with eosinophilic esophagitis. Dis Esophagus 2019;32:doz028. [PMID: 31329864 DOI: 10.1093/dote/doz028] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
13 Reed CC, Corder SR, Kim E, Sanders E, Tappata M, Eluri S, Dellon ES. Psychiatric Comorbidities and Psychiatric Medication Use Are Highly Prevalent in Patients With Eosinophilic Esophagitis and Associate With Clinical Presentation. Am J Gastroenterol 2020;115:853-8. [PMID: 32195733 DOI: 10.14309/ajg.0000000000000597] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
14 Ketchem CJ, Thakkar KP, Xue A, Reddy S, Abramson L, Greenberg SB, Abichandani S, Miller TL, Chang NC, Eluri S, Reed CC, Dellon ES. Older patients with eosinophilic esophagitis have high treatment response to topical steroids. Dig Liver Dis 2021:S1590-8658(21)00809-4. [PMID: 34789398 DOI: 10.1016/j.dld.2021.10.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]